Company Overview and News

 
A-Cap Resources to raise $4 million in underwritten rights offer

2018-04-08 proactiveinvestors.com.au
A-Cap Resources Limited (ASX:ACB) intends to raise around $4 million in a fully underwritten non-renounceable entitlement offer to shareholders.

 
A-Cap Resources acquires nickel-cobalt project as cobalt price hits highest level since 2008

2018-03-23 proactiveinvestors.com.au
A-Cap Resources Limited (ASX:ACB) has entered into an agreement to acquire a nickel-cobalt project in Queensland, Australia.

 
Uranium shares spike as Canadian giant Cameco suspends production

2017-11-09 theage.com.au
The uranium price slump has forced the world's largest producer, Cameco, to temporarily suspend production at two key operations from next year, driving Australian uranium miners' shares skywards.

 
Uranium shares spike as Canadian giant Cameco suspends production

2017-11-09 smh.com.au
The uranium price slump has forced the world's largest producer, Cameco, to temporarily suspend production at two key operations from next year, driving Australian uranium miners' shares skywards.

 
A-Cap Resources has one of world's largest undeveloped uranium deposits, to reveal mining licence details

2017-09-20 proactiveinvestors.com.au
A-Cap Resources Ltd (ASX:ACB) has been granted a trading halt by the ASX, pending details in relation to the company’s mining licence for the Letlhakane Uranium Project (ML2016/16L).

 
Botswana Metals appoints Steven Groves to the board

2017-02-22 proactiveinvestors.com.au
Groves has a Bachelor of Applied Geology (Honours) and completed a Master’s of Economic Geology at the University of Tasmania.

 
3 Points A Jurisdiction Must Meet Before You Invest: Charlie Brookes

2016-09-18 seekingalpha
With money rushing out of the junior resource space, Charlie Brookes, investment director at Arlington Group Asset Management and investment manager at Praetorian Resources, is rushing in-thoughtfully. In this Gold Report interview, he says now is the time to buy and hold, but it is crucial that investors do their homework before investing.

 
A-Cap Resources Ltd granted ASX trading halt

2016-07-11 proactiveinvestors.com.au
A-Cap Resources Ltd (ASX:ACB) has been granted a trading halt by the ASX, pending an announcement in relation to a capital raising. The halt will remain in place until the opening of trade on Wednesday 13th July 2016, or earlier if an announcement is made to the market.

 
A-Cap Resources Ltd requests time for convertible note deed

2016-07-05 proactiveinvestors.com.au
A-Cap Resources Ltd (ASX:ACB) is an exploration and development company that is focused on its Letlhakane Uranium Project in Botswana.

 
A-Cap Resources Ltd heads to market

2016-06-19 proactiveinvestors.com.au
A-Cap Resources Ltd (ASX:ACB) is an exploration and development company that is focused on its Letlhakane Uranium Project in Botswana.

 
A-Cap Resources Ltd gains environmental approval for Letlhakane Uranium Project

2016-05-19 proactiveinvestors.com.au
A-Cap Resources Ltd (ASX:ACB) is an exploration and development company that is focused on its Letlhakane Uranium Project in Botswana.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

20h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...